Ironwood Pharmaceuticals
IRWD
209 hedge funds and large institutions have $1.91B invested in Ironwood Pharmaceuticals in 2021 Q1 according to their latest regulatory filings, with 39 funds opening new positions, 75 increasing their positions, 65 reducing their positions, and 28 closing their positions.
39% more first-time investments, than exits
New positions opened: 39 | Existing positions closed: 28
15% more repeat investments, than reductions
Existing positions increased: 75 | Existing positions reduced: 65
13% more call options, than puts
Call options by funds: $6.42M | Put options by funds: $5.69M
5% more funds holding
Funds holding: 199 → 209 (+10)
0% more funds holding in top 10
Funds holding in top 10: 3 → 3 (0)
0.88% less ownership
Funds ownership: 107.21% → 106.33% (-0.88%)
2% less capital invested
Capital invested by funds: $1.95B → $1.91B (-$41.4M)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
SCM
Sarissa Capital Management
Greenwich,
Connecticut
|
+$24.8M |
| 2 |
Renaissance Technologies
New York
|
+$12M |
| 3 |
GLA
Great Lakes Advisors
Chicago,
Illinois
|
+$10.3M |
| 4 |
LSV Asset Management
Chicago,
Illinois
|
+$10.3M |
| 5 |
HM
HealthCor Management
New York
|
+$7.78M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Westfield Capital Management
Boston,
Massachusetts
|
-$32.8M |
| 2 |
Capital World Investors
Los Angeles,
California
|
-$23.1M |
| 3 |
Man Group
London,
United Kingdom
|
-$16.2M |
| 4 |
AI
Atom Investors
Austin,
Texas
|
-$14.9M |
| 5 |
PCM
Peregrine Capital Management
Minneapolis,
Minnesota
|
-$11.7M |
IRWD Hedge Fund Activity: Q1 2021 in Review
209 of the 5,695 institutional investors tracked by Wall St. Rank reported a position in Ironwood Pharmaceuticals (IRWD) for Q1 2021, worth a combined $1.91B — down 2.1% from $1.95B a quarter earlier.
Buyers outnumbered sellers: 39 funds opened new IRWD positions and 28 closed out — a net gain of 11 holders — while 75 added to existing stakes and 65 trimmed.
The largest buyer was Sarissa Capital Management, adding an estimated $24.8M. The largest seller was Westfield Capital Management, cutting an estimated $32.8M.
- 209 institutional investors held Ironwood Pharmaceuticals (IRWD) as of Q1 2021, up from 199 in Q4 2020.
- Funds reported $1.91B of Ironwood Pharmaceuticals stock for Q1 2021, down 2.1% quarter-over-quarter.
- 39 funds opened new Ironwood Pharmaceuticals positions in Q1 2021 and 28 closed out, a net change of +11 holders.
- The largest Ironwood Pharmaceuticals buyer in Q1 2021 was Sarissa Capital Management, an estimated $24.8M added.
- The largest Ironwood Pharmaceuticals seller in Q1 2021 was Westfield Capital Management, an estimated $32.8M sold.
Based on aggregated 13F filings for Q1 2021.